maduramicin has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, X; Guo, D; Hu, S; Ji, H; Jiang, S; Lin, M; Lv, Y; Peng, L; Song, X; Wang, J; Zhang, J; Zhang, Y; Zuo, R | 1 |
1 other study(ies) available for maduramicin and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Repurposing maduramicin as a novel anticancer and anti-metastasis agent for triple-negative breast cancer as enhanced by nanoemulsion.
Topics: Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Repositioning; Humans; Lactones; Mice; Triple Negative Breast Neoplasms | 2022 |